Home | Site Map | Contact Us | Bookmark  
 
  Single Disease Educational Content
  Multi-Disease
Educational Content
  Other Resources
  About CLDF
 
 

Hepatitis C Virus (HCV)
  Additional content on this specific disease state can be found in the:     Click on another disease specific
area listed above to view content
 

Liver News Library
 
 
 
 
Educational Objectives
After completing this activity, the participants should be better able to:
• Understand the risk factors, natural history and management of hepatitis B
• Analyze the current hepatitis B and hepatitis C treatment algorithms and review future therapies
• Compare and contrast currently available treatment modalities for hepatic encephalopathy
 
Statement of Need/Program Overview
The goal of this program is to improve healthcare providers' competency in understanding the long-term effects and potential liver-related complications of chronic liver diseases. The program will also provide education on management options and outcomes of treatment.
 
Target Audience
This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, physician assistants, and nurse practitioners involved in the care of patients with chronic liver disease.
 

 View details
 
 
Jointly sponsored by Purdue University School of Pharmacy and the Chronic Liver Disease Foundation. This activity supported by independent educational grants from: Genentech, Gilead Sciences, Salix Pharmaceuticals and Vertex Pharmaceuticals.
 
  
 
       

  

Hepatology 2009 Current Perspectives on Chronic Liver Disease   (Recorded East Coast Satellite Broadcast Webcast)
      No CME credit available

  

Treatment of Genotype 1 Nonresponders   (Webcast)
  Presented by: Fred Poordad, MD   No CME credit available

  

Treatment of Hepatitis C Genotype 1 Infected Patients   (Webcast)
  Presented by: Sammy Saab, MD   No CME credit available

  

Optimizing Outcomes: Emerging Therapies for HCV   (Symposium Webcast)
  2006   No CME credit available
 
 
 
HCV 2009  
New>  HCV Genotypes 2 & 3  
New>  Approach to Patients that Failed to Achieve Sustained Viral Response
New>  HCV Genotype 1  
     
 
 

HCV Slide Archive

  
     
 
 
HCV 3rd Edition Slides
Epidemiology and Natural History
Diagnosis and Monitoring
Treatment Special Populations
  Overview   African Americans
  Genotype 1   Hispanic Americans
  Genotype 2/3   HCV/HIV Co-infected
  Retreatment   HCV and Alcohol
  Side Effects   Liver Transplant
  Emerging Therapies   Acute Infection
 
HCV 2nd Edition Slides
Epidemiology and Natural History Diagnosis and Monitoring
Treatment Side Effects and Management Treatment
Special Patient Populations  
   
HCV - AASLD 2005    
Emerging Therapies in HCV:'Building the Bridge to Improved Outcomes'
Ribavirin Analogues  
Immunomodulators  
Caspase Inhibitors  
Specific Small Molecule Inhibitors  
   
HCV 1st Edition Slides
Epidemiology and Natural History  
Molecular Tools for the Diagnosis and Monitoring of Hepatitis C
Treatment of HCV  
Prevention of Coinfection/Superinfection  
Early Assessment of Response  
Histologic Response to Treatment  
Adherence and SE Management  
 
     
 
 
  1. Acute Hepatitis C: Diagnosis and Management
    McLean OR, Herrera JL. PRACTICAL GASTROENTEROLOGY • SEPTEMBER 2007;31:66-77.

  2. Management of Hepatitis C Virus Infection
    Tran LC, Woods AR, Herrera JL. Drug Benefit Trends 2004;16:266-276.

  3. Hepatitis C: Who should be treated?
    Smith JR, Herrera JL. PRACTICAL GASTROENTEROLOGY • SEPTEMBER 2002;26:14-21.

  4. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C
    Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK; International Hepatitis Interventional Therapy Group. Am J Gastroenterol. 2003 Nov;98(11):2354-62.

  5. Increased prevalence of depression in hepatitis C infection patients
    Hjerrild S, Renvillard SG, Leutscher PD, Videbech P. Ugeskr Laeger. 2010 Jun 21;172(25):1889-1893.

  6. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros
    Masuzaki R, Yoshida H, Omata M. Dig Liver Dis. 2010 Jul;42 Suppl 3:S281-6.

  7. New Frontiers of HCV Therapy in HIV/HCV Co-infection
    Amorosa VK. Curr HIV/AIDS Rep. 2010 Jun 20. [Epub ahead of print]

  8. Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy
    Hofer H, Aydin I, Neumueller-Guber S, Mueller C, Scherzer TM, Staufer K, Steindl-Munda P, Wrba F, Ferenci P. J Viral Hepat. 2010 Jun 21. [Epub ahead of print]

  9. Gender influence on treatment of chronic hepatitis C genotype 1
    Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, Sampaio JP, Batah PN, Barbosa DV, Ferraz ML, Silva AE. Rev Soc Bras Med Trop. 2010 Jun;43(3):217-23.

  10. Treatment options for HCV nonresponders and relapse patients
    Pearlman BL, Sjogren MH. Gastroenterol Hepatol (N Y). 2010 Mar;6(3 Suppl 6):1-12.

  11. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
    Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Carlos Lopez-Talavera J, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Hepatology. 2010 May 14. [Epub ahead of print]

  12. Treatment of Hepatitis C in Renal Transplantation Candidates: A Single-Center Experience
    Werner T, Aqel B, Balan V, Byrne T, Carey E, Douglas D, Heilman RL, Jorge. Transplantation. 2010 Jun 22. [Epub ahead of print]

  13. Evidence for separation of HCV subtype 1a into two distinct clades
    Pickett BE, Striker R, Lefkowitz EJ. J Viral Hepat. 2010 Jun 21. [Epub ahead of print]

  14. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy
    Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, Torres DM, Koury K, Goteti VS, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS. Hepatology. 2010 Jun 1. [Epub ahead of print]

  15. Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS; and the HALT?C Trial Group. Hepatology. 2010 May 14. [Epub ahead of print]

  16. Treatment of hepatitis C in 2011: what can we expect?
    Shiffman ML. Curr Gastroenterol Rep. 2010 Feb;12(1):70-5.

  17. Boceprevir, an NS3 protease inhibitor of HCV
    Berman K, Kwo PY. Clin Liver Dis. 2009 Aug;13(3):429-39.

  18. The healthcare burden imposed by liver disease in aging Baby Boomers
    Davis GL, Roberts WL. Curr Gastroenterol Rep. 2010 Feb;12(1):1-6.

  19. Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality from Liver Cancer in the United States
    Younossi ZM, Stepanova M. Clin Gastroenterol Hepatol. 2010 Apr 29. [Epub ahead of print]

  20. Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of IFN therapy for chronic hepatitis C
    Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S; Hokuriku Liver Study Group. Gastroenterology. 2010 Apr 28. [Epub ahead of print]

  21. IL28B Polymorphism Improves Viral Kinetics and Is the Strongest Pre-treatment Predictor of SVR in HCV-1 Patients
    Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Gastroenterology. 2010 Apr 15. [Epub ahead of print]

  22. Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance
    Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Gut Liver. 2009 Jun;3(2):108-15. Epub 2009 Jun 30.

  23. Preclinical Characterization of Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of HCV NS3 Protease
    Tong X, Arasappan A, Bennett F, Chase R, Feld B, Guo Z, Hart A, Madison V, Malcolm B, Pichardo J, Prongay A, Ralston R, Skelton A, Xia E, Zhang R, Njoroge F. Antimicrob Agents Chemother. 2010 Mar 22. [Epub ahead of print]

  24. Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS
    Farnik H, El-Duweik J, Welsch C, Sarrazin C, Lötsch J, Zeuzem S, Geisslinger G, Schmidt H. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4001-6.

  25. Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data
    Wise M, Finelli L, Sorvillo F. Public Health Rep. 2010 May-Jun;125(3):414-22.

  26. Review article: HCV - STAT-C era of therapy
    Lange CM, Sarrazin C, Zeuzem S. Aliment Pharmacol Ther. 2010 Mar 31. [Epub ahead of print]

  27. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection
    Cross TJ, Quaglia A, Nolan J, Hughes S, Harrison PM. J Med Virol. 2010 May;82(6):958-64

  28. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus
    Gentile I, Carleo MA, Borgia F, Castaldo G, Borgia G. Expert Opin Investig Drugs. 2010 Jan;19(1):151-9.

  29. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin
    Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. J Med Virol. 2010 Apr;82(4):575-82.

  30. Telaprevir for previously treated chronic HCV infection
    McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM; PROVE3 Study Team. N Engl J Med. 2010 Apr 8;362(14):1292-303.

  31. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435
    Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA. Antimicrob Agents Chemother. 2010 May;54(5):1878-87. Epub 2010 Feb 22.

  32. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy
    Anastasiou J, Alisa A,Virtue,S, Portmann,B, Murray-Lyon I, Williams R. Eur J Gastroenterol & Hepatol 2010;22:474-480

  33. Hepatitis C and metabolic syndrome
    Aparcero López R, Campo JA, Romero-Gómez M. Gastroenterol Hepatol. 2010 Mar 3. [Epub ahead of print]

  34. Genetic polymorphism and response to treatment in chronic hepatitis C: The future of personalized medicine
    Asselah T. J Hepatol. 2010 Jan 7. [Epub ahead of print]

  35. Effect of hemodialysis schedules and membranes on hepatocyte growth factor and hepatitis C virus RNA levels
    Barril G, Bartolomé J, Sanz P, Buoncristiani E, Traver JA, Selgas R, Buoncristiani U, Castillo I, Quiroga JA, Carreño V. J Med Virol. 2010 Mar 24;82(5):763-767. [Epub ahead of print]

  36. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions
    Bini EJ, Perumalswami PV. Hepatology. 2009 Nov 30. [Epub ahead of print]

  37. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: An analysis of the Swiss Hepatitis C Cohort Study
    Bruggmann P, Dampz M, Gerlach T, Kravecz L, Falcato L. Drug Alcohol Depend. 2010 Mar 22. [Epub ahead of print]

  38. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma
    Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Mayo Clin Proc. 2010 Apr;85(4):349-56.

  39. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy
    Cesaro S, Bortolotti F, Petris MG, Brugiolo A, Guido M, Carli M. Pediatr Blood Cancer. 2010 Feb 1. [Epub ahead of print]

  40. Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients
    Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, Tavis JE; for the Virahep-C Study Group. PLoS One. 2010 Feb 3;5(2):e9032

  41. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials
    Fabrizi F, Dixit V, Messa P, Martin P. J Med Virol. 2010 Mar 24;82(5):768-775. [Epub ahead of print]

  42. Multiple Clusters of Hepatitis Virus Infections Associated with Anesthesia for Outpatient Endoscopy Procedures
    Gutelius B, Perz JF, Parker MM, Hallack R, Stricof R, Clement EJ, Lin Y, Xia GL, Punsalang A, Eramo A, Layton M, Balter S. Gastroenterology. 2010 Mar 27. [Epub ahead of print]

  43. Molecular epidemiology of health care-associated transmission of hepatitis B and C viruses
    Holmberg SD. Clin Liver Dis. 2010 Feb;14(1):37-48

  44. Hepatitis B and Hepatitis C Prevalence and Treatment Referral Among Asian Americans Undergoing Community-Based Hepatitis Screening
    Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM. Am J Public Health. 2010 Feb 10. [Epub ahead of print]

  45. Treatment of hepatitis C in children
    Jara P, Hierro L. Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):51-61.

  46. Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin
    Levast M, Larrat S, Thelu MA, Nicod S, Plages A, Cheveau A, Zarski JP, Seigneurin JM, Morand P, Leroy V. J Med Virol. 2010 Mar 24;82(5):747-754. [Epub ahead of print]

  47. The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C
    Liu CH, Liang CC, Liu CJ, Hsu SJ, Lin JW, Chen SI, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH. Kidney Int. 2010 Mar 31. [Epub ahead of print]

  48. Occupational exposure of health care personnel to hepatitis B and hepatitis C: prevention and surveillance strategies
    Maccannell T, Laramie AK, Gomaa A, Perz JF. Clin Liver Dis. 2010 Feb;14(1):23-36.

  49. Management of Acute Hepatitis C
    Maheshwari A, Thuluvath PJ. Clin Liver Dis. 2010 Feb;14(1):169-176.

  50. Performance of the AST-to-Platelet Ratio Index as a Noninvasive Marker of Fibrosis in Pediatric Patients With Chronic Viral Hepatitis
    McGoogan KE, Smith PB, Choi SS, Berman W, Jhaveri R

  51. Infection Control Guidelines for Prevention of Health Care-Associated Transmission of Hepatitis B and C Viruses
    Michelin A, Henderson DK. Clin Liver Dis. 2010 Feb;14(1):119-136.

  52. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features
    Morsica G, Ancarani F, Bagaglio S, Maracci M, Cicconi P, Cozzi Lepri A, Antonucci G, Bruno R, Santantonio T, Tacconi L, Baldelli F, Piscopo R, Santoro D, Lazzarin A, D'Arminio Monforte A; HepaICONA; ICONA Study Groups. Infection. 2009 Oct;37(5):455-60.

  53. Hepatitis C and hepatic steatosis
    Patel JH, Cobbold JF, Thomas HC, Taylor-Robinson SD. QJM. 2010 Feb 4. [Epub ahead of print]

  54. US Outbreak Investigations Highlight the Need for Safe Injection Practices and Basic Infection Control
    Perz JF, Thompson ND, Schaefer MK, Patel PR. Clin Liver Dis. 2010 Feb;14(1):137-51

  55. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals
    Seden K, Back D, Khoo S. J Antimicrob Chemother. 2010 Mar 23. [Epub ahead of print]

  56. Epidemiology of Hepatitis B and C Viruses: A Global Overview
    Te HS, Jensen DM. Clin Liver Dis. 2010 Feb;14(1):1-21.

  57. Terlipressin therapy for renal failure in cirrhosis
    Triantos C, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli,L, Leandro,G, Patch D, Burroughs A. Eur J Gastroenterol & Hepatol 2010;22:481-486.

  58. The Treatment of Chronic Hepatitis C Virus Infection in HIV Co-infection
    Vogel M, Rockstroh J. Eur J Med Res. 2009 Dec 14;14(12):507-15.

  59. Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients
    Winters MA, Chary A, Eison R, Asmuth D, Holodniy M. J Med Virol. 2010 Mar 24;82(5):791-798. [Epub ahead of print]

  60. Genetic polymorphism and response to treatment in chronic hepatitis C: The future of personalized medicine
    Asselah T. J Hepatol. 2010 Jan 7. [Epub ahead of print]

  61. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions
    Bini EJ, Perumalswami PV. Hepatology. 2009 Nov 30. [Epub ahead of print]

  62. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy
    Cesaro S, Bortolotti F, Petris MG, Brugiolo A, Guido M, Carli M. Pediatr Blood Cancer. 2010 Feb 1. [Epub ahead of print]

  63. Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients
    Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, Tavis JE; for the Virahep-C Study Group. PLoS One. 2010 Feb 3;5(2):e9032.

  64. Molecular epidemiology of health care-associated transmission of hepatitis B and C viruses
    Holmberg SD. Clin Liver Dis. 2010 Feb;14(1):37-48.

  65. Hepatitis B and Hepatitis C Prevalence and Treatment Referral Among Asian Americans Undergoing Community-Based Hepatitis Screening
    Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM. Am J Public Health. 2010 Feb 10. [Epub ahead of print]

  66. Treatment of hepatitis C in children
    Jara P, Hierro L. Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):51-61.

  67. Occupational exposure of health care personnel to hepatitis B and hepatitis C: prevention and surveillance strategies
    Maccannell T, Laramie AK, Gomaa A, Perz JF. Clin Liver Dis. 2010 Feb;14(1):23-36.

  68. Management of Acute Hepatitis C
    Maheshwari A, Thuluvath PJ. Clin Liver Dis. 2010 Feb;14(1):169-176

  69. Performance of the AST-to-Platelet Ratio Index as a Noninvasive Marker of Fibrosis in Pediatric Patients With Chronic Viral Hepatitis
    McGoogan KE, Smith PB, Choi SS, Berman W, Jhaveri R

  70. Infection Control Guidelines for Prevention of Health Care-Associated Transmission of Hepatitis B and C Virusese
    Michelin A, Henderson DK. Clin Liver Dis. 2010 Feb;14(1):119-136

  71. Hepatitis C and hepatic steatosis
    Patel JH, Cobbold JF, Thomas HC, Taylor-Robinson SD. QJM. 2010 Feb 4. [Epub ahead of print]

  72. US Outbreak Investigations Highlight the Need for Safe Injection Practices and Basic Infection Control
    Perz JF, Thompson ND, Schaefer MK, Patel PR. Clin Liver Dis. 2010 Feb;14(1):137-51.

  73. Epidemiology of Hepatitis B and C Viruses: A Global Overview
    Te HS, Jensen DM. Clin Liver Dis. 2010 Feb;14(1):1-21.

  74. The Treatment of Chronic Hepatitis C Virus Infection in HIV Co-infection
    Vogel M, Rockstroh J. Eur J Med Res. 2009 Dec 14;14(12):507-15

  75. Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C
    Gambarin-Gelwan M, Jacobson IM. J Viral Hepat 2008;9:623-33.

  76. Host Genetics, Steatosis and Insulin Resistance among African Americans and Caucasian Americans with Hepatitis C Virus Genotype-1 Infection
    Iuliano AD, Feingold E, Wahed AS, Kleiner DE, Belle SH, Conjeevaram HS, Zmuda J, Liang TJ, Yee LJ. Intervirology 2009;52:49-56.

  77. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
    John G. McHutchison, M.D., Gregory T. Everson, M.D., Stuart C. Gordon, M.D., Ira M. Jacobson, M.D., Mark Sulkowski, M.D., Robert Kauffman, M.D., Lindsay McNair, M.D., John Alam, M.D., Andrew J. Muir, M.D., for the PROVE1 Study Team. N ENGL J Med 2009;360:1827-1838

  78. Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
    Christophe Hézode, M.D., Nicole Forestier, M.D., Geoffrey Dusheiko, M.D., Peter Ferenci, M.D., Stanislas Pol, M.D., Tobias Goeser, M.D., Jean-Pierre Bronowicki, M.D., Marc Bourlière, M.D., Shahin Gharakhanian, M.D., Leif Bengtsson, B.S.C., Lindsay McNair, M.D., M.P.H., Shelley George, M.D., Tara Kieffer, Ph.D., Ann Kwong, Ph.D., Robert S. Kauffman, M.D., Ph.D., John Alam, M.D., Jean-Michel Pawlotsky, M.D., Ph.D., Stefan Zeuzem, M.D., for the PROVE2 Study Team. N ENGL J Med 2009;360:1839-1850.

  79. Adherence to medication for chronic hepatitis C: Building on the model of human immunodeficiency virus antiretroviral adherence research
    Weiss JJ, Bräu N, Stivala A, Swan T, Fishbein D.Ailiment Pharmacol Ther. 2009 Mar 26 (Epub ahead of print)

  80. Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection
    Puchner KP, Berg T. Z Gastroenterol. 2009;47:446-456. Epub 2009 May 5.

  81. Neuropsychological performance in patients with human immunodeficiency (HIV) and neuropsychological hepatitis C virus (HCV) coinfection
    Failde J, Rodríguez Alvarez M, López Castro J, Simón López M. Neurologia. 2009;3:154-9.

  82. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men
    van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, Vogel M, Baumgarten A, Chaix ML, Fisher M, Gotz H, Matthews GV, Neifer S, White P, Rawlinson W, Pol S, Rockstroh J, Coutinho R, Dore GJ, Dusheiko GM, Danta M. Gastroenterol. 2009;136:1609-17.

  83. Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection
    Gonzalez SA, Fiel MI, Sauk J, Canchis PW, Liu RC, Chiriboga L, Yee HT, Jacobson IM, Talal AH. J Viral Hepat. 2009;2:141-8.

  84. Peginterferon alfa-2b and Ribavirin: Effective in Patients with Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
    Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J; The Epic Study Group. Gasterenterol 2009;Jan 22 (Epub ahead of print)

  85. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors
    Kwong AD, McNair L, Jacobson I, George S.Curr Opin Pharmacol 2008;5:522-31.

  86. Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study
    Loras C, Saro C, Gonzalez-Huix F, et al. Am J Gastroenterol 2009;104:57-63.

  87. Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
    Di Bisceglie A, Shiffman M, Everson G, et al for the HALT-C Trial Investigators. N Engl J Med 2008;359:2429-2441.

  88. Exceeding the limits of liver histology markers
    Mehta S, Lau B, Afdhal N and Thomas D. J Hepatol 2009;50:36-41.

  89. A Randomized, Prospective Trial of Ribavirin 400 mg/Day Versus 800 mg/Day in Combination with Peginterferon Alfa-2a in Hepatitis C Virus Genotypes 2 and 3
    Ferenci P, Brunner H, Laferl H, Scherzer T, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K, for the Austrian Hepatitis Study Group. HEPATOLOGY;47:1816-1823.

  90. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3
    Poustchi H, Negro F, Hui J, Homer I, Cua Y, Brandt L, Kench J, George J. J Hepatol 2008;48:28-34.

  91. Combination of Oxidative Stress and Steatosis Is a Risk Factor for Fibrosis in Alcohol-Drinking Patients With Chronic Hepatitis C
    Vidali M, Occhino G, Ivaldi A, Rigamonti C, Sartori M, Albano E. Am J Gastroenterol 2008;103:147-153.

  92. Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C
    McHutchinson J, Dusheikko G, , Schiffman M, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon S, Campbell F, Theodore D, Blackman N, Jenkins J, Afdhal N for the TPL102357 Study Group. N ENGL J MED 357,22:2227-2236.

  93. Treatment Extension to 72 Weeks of Peginterferon and Ribavirin in Hepatitis C Genotype 1-Infected Slow Responders
    Pearlman B, Ehleben C, Saifee S. HEPATOLOGY 2007;6:1688-1694.

  94. Predictors of Response of U.S. Veterans to Treatment for the Hepatitis C Virus
    Backus LI, Boothroyd DB, Phillips BR, Mole LA. HEPATOLOGY 2007 ; 46:37-47.

  95. Telaprevir and Pegylated Interferon-alpha-2a Inhibit Wild-Type and Resistant Genotype 1 Hepatitis C Virus Replication in Patients
    Kieffer T, Sarrazin C, Miller J, Welker M, Forestier N, Reesink H, Kwong A, Zuezem S

  96. Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
    Schiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola´ R, Shafran SD, Barange K, Lin A, Sorman A, Zeuzem S, for the ACCELERATE Investigators. NEJM 2007 ; 357:124-134

  97. Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication
    Huang J, Dai C, Hwang, Ho C, Hsiao P, Hsieh M, Lee L, Lin Z, Chen S, Hsieh M, Wang L, Shin S, Chang W, Chuang W, Yu M. Am J Gastroenterol 2007 ; 102:1237-1243

  98. Cognitive Function Does Not Worsen During Pegylated Interferon and Ribavirin Retreatment of Chronic Hepatitis C
    Fontana RJ, Bieliauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK, Lok AS, Kronfol Z, Padmanabhan L, and the HALT-C Trial Group. HEPATOLOGY 2007 ; 45:1154-1163

  99. The Effects of HCV Infection and Management on Health-Related Quality of Life
    Younossi Z, Kallman J, Kincaid J. HEPATOLOGY 2007;45:806-816

  100. HCV RNA Detection by TMA during the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial
    C. Morishima et al. HEPTOLOGY, Vol. 44, No. 2, 2006:360-367

  101. Impact of Disease Severity on Outcome of Antiviral Therapy for Chronic Hepatitis C: Lessons From the HALT-C Trial
    Everson G, Hoefs J, Seeff L, Bonkovsky H, Naishadham D, Schiffman M, Kahn J, Lok A, De Bisceglie, Lee W, Dienstag J, Ghany M, Morishima C, and the HALT-C Trial Group. HEPATOLOGY 2006 ; 44:1675-1684

  102. Cost-Effectiveness of Hematologic Growth Factors for Anemia Occurring During Hepatitis C Combination Therapy
    R Del Rio, Anthony B. Post, Mendel Singer. Hepatology 2006; 44:1598-1606

  103. Steatosis and Progression of Fibrosis in Untreated Patients With Chronic Hepatitis C Infection
    P. Perumalswami et al. HEP, Vol 43, No 4 (April 2006); 780-787

  104. Treatment with daily concensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study
    M. Cornberg et al. Journal of Hepatology 44 (Feb 2006) 291-301

  105. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    S. Zeuzem et al J Hep 44 (January 2006) 97-103

  106. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse
    M Gerotto et al, J Hep 44 (January 2006) 83-87

  107. HCV/Clinical: Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin
    Ferenci P et al J Hep 43 (2005) 425-433.

  108. HCV/Clinical: Pilot study of interferon gamma for chronic hepatitis C
    A. Soza, T. Heller, M. Ghany, G. Lutchman, T. Liang, J. Germain, H. Hsu, Y. Park, J. Hoofnagle Journal of Hepatology 43 (2005) 67-71.

  109. HCV/Clinical: Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C
    WL Krawitt et al. J.Hep 43 (2005) 243-249

  110. HCV/Clinical: Adult living donor liver transplantation: Who is the ideal donor and recipient?
    Henkie P et al. J Hep. Volume 43 (2005) 13-17
   

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2009 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource
for US healthcare providers only. Use of this Web site is governed by the CLD Foundation terms of use and privacy statement.